Health Technology · Pharmaceuticals: Major · NSE: PARNAXLAB · data 2026-10-09
Parnax Lab Limited
Health check: Strong (6.5/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹115.16
Market cap
₹129 cr
P/E
14.8
P/B
—
ROE
13.2%
ROCE
18.0%
Debt / equity
0.87
Dividend yield
0.00%
1-year return
6.6%
52-week high
₹149.5
52-week low
₹104
Operating margin
6.3%
Growth
| Revenue (last 12 months) | ₹252 cr |
| Net profit (last 12 months) | ₹9 cr |
| Sales growth, 3 years (yearly) | 14.0% |
| Profit growth, 3 years (yearly) | 11.0% |
Similar companies
Bal Pharma Limited (BALPHARMA) · Quest Laboratories Ltd. (QUESTLAB) · Krebs Biochemicals & Industries Ltd. (KREBSBIO) · Alpa Laboratories Limited (ALPA) · Makers Laboratories Ltd (MAKERSL)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open PARNAXLAB in NSE Scanner →